Health Trials

Hormone Receptor Positive Breast Adenocarcinoma

2

Review clinical trials related to Hormone Receptor Positive Breast Adenocarcinoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.

Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Aktis Oncology, Inc.Updated: Jul 10, 2026Locations: 12
Eligibility criteria

Histologic or cytologic confirmation of locally advance or metastatic disease [+6]

Prior treatment with a therapeutic radiopharmaceutical [+4]

Read more
Status: Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for HR+/HER2- aBC. In consideration of the complexity of data collected and different objectives of the study, this master protocol foresees different sub-studies, which encompasses different methodologies for data collection, data extraction and analyses.

Participants needed: 3,500
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoUpdated: Feb 3, 2025Locations: 24
Eligibility criteria

Diagnosis of HR+/HER2- advanced Breast Cancer (aBC), as defined as at least 1% e... [+1]

Less than 3 months of follow up from the CDK4/6i start to the date of data cut-o... [+2]

Read more